Semaglutide does suppress appetite, but calling it “just” an appetite suppressant seriously undersells what the drug does. It works through at least half a dozen distinct biological pathways, from slowing digestion to rewiring how your brain responds to food cravings to improving blood sugar regulation. Traditional appetite suppressants like phentermine are stimulants that push hunger down through a single mechanism and carry abuse potential. Semaglutide mimics a hormone your body already makes, and its effects reach far beyond the simple question of whether you feel hungry.
How It Differs From Traditional Appetite Suppressants
Older weight loss drugs like phentermine are classified as stimulants and controlled substances (Schedule IV) because they carry some risk of dependence. They work by flooding the brain with certain chemicals that temporarily blunt hunger signals. They’re approved only for short-term use, typically a few months, and once you stop, the appetite suppression disappears.
Semaglutide is not a stimulant, not a controlled substance, and works through an entirely different system. It mimics GLP-1, a hormone your gut naturally releases after eating. That hormone has receptors scattered across your digestive tract, pancreas, heart, kidneys, and multiple regions of the brain. When semaglutide activates those receptors, it triggers a cascade of effects that go well beyond reducing hunger. The drug is approved for long-term use, and its benefits appear to accumulate over time rather than fade.
What Happens in the Brain
The brain effects of semaglutide are arguably where the biggest difference from a simple appetite suppressant shows up. GLP-1 receptors exist in areas of the brain that control energy balance, including several regions of the hypothalamus and the brainstem. When semaglutide reaches these areas, it activates neurons that signal fullness while simultaneously shutting down neurons that drive hunger. This is more precise than a stimulant flooding your system. It’s targeted signaling through circuits your body already uses to regulate eating.
But here’s the part that surprises most people: semaglutide also acts on the brain’s reward system. GLP-1 receptors sit in the nucleus accumbens and the ventral tegmental area, structures deeply involved in motivation, pleasure, and craving. Normally, eating something highly palatable (think sugar or ultra-processed food) causes a spike of dopamine in these reward centers. Animal studies show that when a GLP-1 drug is active, that dopamine spike is largely squelched. The food still tastes the same, but the neurological “hit” you get from it is blunted.
This is what many patients describe as the quieting of “food noise,” the constant background hum of thinking about food, planning meals, craving snacks. It’s not just that they feel less hungry. The obsessive pull toward food loosens its grip. Scientists don’t yet have a formal definition for food noise, and the research into exactly how synthetic GLP-1 produces this effect is still early. But the patient experience is remarkably consistent.
Effects Beyond the Brain
Semaglutide slows gastric emptying, meaning food stays in your stomach longer after a meal. This creates a prolonged feeling of fullness that works alongside the brain-based appetite effects. One study found that patients on semaglutide were about five times more likely to have significant food remaining in their stomachs compared to people not taking the drug. This isn’t just a minor tweak. It fundamentally changes how quickly you feel ready to eat again.
In the pancreas, semaglutide enhances insulin release in a glucose-dependent way, meaning it helps your body produce more insulin when blood sugar is high but doesn’t push insulin out when levels are normal. It also suppresses glucagon, a hormone that raises blood sugar. This dual action is why semaglutide was originally developed for type 2 diabetes, and it’s a function that no traditional appetite suppressant has ever offered.
Cardiovascular and Kidney Protection
Perhaps the strongest evidence that semaglutide is not just an appetite suppressant comes from its effects on the heart and kidneys. The SELECT trial studied people with obesity and established heart disease (but not diabetes) and found that semaglutide reduced major cardiovascular events, including heart attacks, strokes, and cardiovascular death, by 20%. This led the FDA to approve Wegovy specifically for cardiovascular risk reduction, an indication that has nothing to do with appetite.
The FLOW trial, published in the New England Journal of Medicine, tested semaglutide in people with type 2 diabetes and chronic kidney disease. Patients on semaglutide had a 24% lower risk of major kidney events, a composite that included kidney failure, significant loss of kidney function, and death from kidney or cardiovascular causes. Their rate of kidney function decline slowed substantially compared to placebo. These are organ-protective effects that operate through mechanisms researchers are still fully mapping out, but they clearly extend beyond anything related to hunger.
Potential Effects on Addiction and Cravings
The most unexpected finding about GLP-1 drugs may be their apparent effect on addictive behaviors unrelated to food. A large study analyzing health records of over 600,000 veterans with type 2 diabetes found that those taking GLP-1 medications had a 14% lower risk of developing any substance use disorder compared to those on other diabetes drugs. The reductions were consistent across substances: 18% for alcohol, 20% for cocaine and nicotine, and 25% for opioids.
Among veterans who already had a substance use disorder, GLP-1 use was associated with 30% fewer emergency department visits, 25% fewer hospitalizations, 40% fewer overdoses, and 50% fewer drug-related deaths over three years. Researchers at Washington University School of Medicine believe these drugs work against craving itself rather than against any specific substance. As lead researcher Ziyad Al-Aly put it, the drug “blunts that craving that pulls people toward whatever they’re addicted to.” Clinical trials testing GLP-1 drugs specifically as addiction treatments are being planned, but the observational data is already striking.
What the FDA Actually Approved It For
The current list of FDA-approved uses for Wegovy (the weight management brand of semaglutide) reflects just how far the drug has moved beyond appetite suppression:
- Weight management in adults and adolescents 12 and older with obesity, or adults with overweight plus at least one weight-related health condition
- Cardiovascular risk reduction in adults with established heart disease and obesity or overweight
- Liver disease treatment for adults with a specific form of fatty liver disease (formerly called NASH) with moderate to advanced scarring
Ozempic, the diabetes-focused brand, is separately approved for blood sugar management in type 2 diabetes. Each of these approvals represents a distinct biological effect, and none of them would exist if semaglutide were simply making people less hungry.
So What Is It, Then?
Semaglutide is best understood as a hormone mimic with system-wide effects. It does suppress appetite, and powerfully so, through both brain signaling and slowed digestion. But it also reshapes how the brain processes reward and craving, improves blood sugar control through direct pancreatic action, protects the heart and kidneys through mechanisms that aren’t fully explained by weight loss alone, treats liver fibrosis, and may even reduce vulnerability to addiction. Calling it an appetite suppressant is like calling a smartphone a calculator. Technically accurate, but missing most of the picture.